| Literature DB >> 29183352 |
Koetsu Inoue1, Tatsuya Ueno2, Daisuke Douchi2, Kentaro Shima2, Shinji Goto2, Michinaga Takahashi2, Takanori Morikawa3, Takeshi Naitoh3, Chikashi Shibata4, Hiroo Naito2.
Abstract
BACKGROUND: The Tokyo Guidelines 2013 classifies acute cholecystitis (AC) into three grades and recommends appropriate therapy for each grade. For grade II AC, either early laparoscopic cholecystectomy (LC) or percutaneous transhepatic gallbladder drainage (PTGBD) should be performed. This study aimed to identify the risk factors for difficulty of LC for treating grade II AC.Entities:
Keywords: Acute cholecystitis; Laparoscopic cholecystectomy; Tokyo guidelines 2013
Mesh:
Year: 2017 PMID: 29183352 PMCID: PMC5706415 DOI: 10.1186/s12893-017-0319-6
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.102
Classification of acute cholecystitis by the Tokyo guidelines 2013
| Grade | Definition | |
|---|---|---|
| I (Mild) | Acute cholecystitis that does not meet the criteria for Grade III or Grade II | |
| Acute cholecystitis in a healthy patient with no organ dysfunction. Inflammatory changes in the gallbladder are mild, making cholecystectomy a safe and low-risk procedure. | ||
| II (Moderate) | Grade II acute cholecystitis is associated with any one of the following conditions | |
| 1 | Elevated white blood cell count (>18,000/mm4) | |
| 2 | Palpable tender mass in the right upper abdominal quadrant | |
| 3 | Duration of complaints > 72 h | |
| 4 | Marked local inflammation (gangrenous cholecystitis, pericholecystic abscess, hepatic abscess, biliary peritonitis, emphysematous cholecystitis) | |
| III (Severe) | Grade III acute cholecystitis associated with dysfunction of any one of the following organs/systems | |
| 1 | Cardiovascular dysfunction defined as hypotension requiring treatment with ≥ 5 μg/kg per min of dopamine or any dose of norepinephrine | |
| 2 | Neurologic dysfunction defined as decreased level of consciousness | |
| 3 | Respiratory dysfunction defined as a PaO2/FiO2 ratio of <300 | |
| 4 | Renal dysfunction defined as oliguria or creatinine level of > 2.0 mg/dl | |
| 5 | Hepatic dysfunction defined as PT-INR of > 1.5 | |
| 6 | Hematologic dysfunction defined as platelet count of <100,000/mm3 | |
Fig. 1Treatment according to AC grade and response. LC: Laparoscopic cholecystectomy, GB: Gallbladder
Fig. 2Study flow chart. AC: Acute cholecystitis. LC: Laparoscopic cholecystectomy. PTGBD: Percutaneous transhepatic gallbladder drainage. DLC: Difficult laparoscopic cholecystectomy. NDLC: Nondifficult laparoscopic cholecystectomy
Comparison of patient clinical characteristics
| Variable | DLC group | NDLC group |
|
|---|---|---|---|
| ( | ( | ||
| Age, years | 68.8 ± 2.42 | 66.7 ± 1.50 | 0.455 |
| Male, | 28 (82.4) | 51 (58.0) | 0.011 |
| BMI | 24.5 ± 0.672 | 25.2 ± 0.418 | 0.389 |
| Interval between symptom onset and operation, hours | 126 ± 9.04 | 70.3 ± 5.62 | < 0.0001 |
| Interval between symptom onset and admission, hours | 65.6 ± 7.07 | 32.9 ± 4.40 | 0.0001 |
| Fever on admission, | 0.715 | ||
| No | 24 (70.6) | 65 (73.9) | |
| Yes | 10 (29.4) | 23 (26.1) | |
| Abdominal pain on admission, | 0.409 | ||
| No | 1 (2.9) | 6 (6.8) | |
| Yes | 33 (97.1) | 82 (93.2) | |
| ASA score, | 0.949 | ||
| <3 | 11 (32.4) | 29 (32.9) | |
| ≥3 | 23 (67.6) | 59 (67.1) | |
| Performance status, | 0.695 | ||
| <3 | 32 (94.1) | 81 (92.1) | |
| ≥3 | 2 (5.9) | 7 (7.9) | |
| Anticoagulant therapy, | 10 (29.4) | 12 (13.6) | 0.042 |
| Hypertension, | 12 (35.3) | 39 (44.3) | 0.365 |
| Diabetes mellitus, | 9 (26.5) | 20 (22.7) | 0.663 |
Continuous variables are presented as mean ± SEM
BMI Body mass index, ASA American Society of Anesthesiologists
Comparison of laboratory data and imaging findings
| Variable | DLC group | NDLC group |
|
|---|---|---|---|
| (n = 34) | ( | ||
| Laboratory data | |||
| White blood cells, 103/μL | 14.6 ± 0.893 | 14.3 ± 0.555 | 0.780 |
| Hemoglobin, g/dL | 13.9 ± 0.326 | 14.0 ± 0.203 | 0.791 |
| Platelets, 103/μL | 198 ± 9.42 | 201 ± 5.86 | 0.788 |
| CRP, mg/dL | 13.0 ± 1.60 | 10.1 ± 0.993 | 0.120 |
| Total bilirubin, mg/dL | 1.76 ± 0.195 | 1.45 ± 0.121 | 0.19 |
| AST, IU/L | 42.8 ± 21.0 | 79.9 ± 13.0 | 0.136 |
| ALT, IU/L | 41.9 ± 14.5 | 70.0 ± 9.0 | 0.102 |
| ALP, IU/L | 310 ± 39.0 | 321 ± 24.2 | 0.816 |
| γ-GTP, IU/L | 113 ± 28.3 | 114 ± 17.6 | 0.984 |
| Radiographic and ultrasonographic findings | |||
| GB wall thickness, mm | 6.53 ± 0.435 | 5.85 ± 0.271 | 0.183 |
| GB stone and/or sludge, n (%) | 34 (100) | 84 (95.5) | 0.206 |
Continuous variables are presented as mean ± SEM
CRP C-reactive protein, AST Aspartate aminotransferase, ALT Alanine aminotransferase, ALP Alkaline phosphatase, γ-GTP Gamma-glutamyl transpeptidase, GB Gallbladder
Comparison of perioperative characteristics
| Variable | DLC group | NDLC group |
|
|---|---|---|---|
| ( | (n = 89) | ||
| Operating time, min | 178 ± 6.32 | 122 ± 3.93 | <0.0001 |
| Operating time ≥ 180 min, n (%) | 18 (52.9) | 0 (0) | |
| Blood loss, ml | 354 ± 31.4 | 45.1 ± 19.1 | <0.0001 |
| Blood loss ≥300 ml, n (%) | 15 (44.1) | 0 (0) | |
| Open conversion, n (%) | 16 (47.1) | 0 (0) | <0.0001 |
| Subtotal cholecystectomy and/or mucoclasis, n (%) | 20 (58.8) | 19 (21.6) | <0.0001 |
| Necrosis and/or abscess, n (%) | 28 (82.4) | 65 (73.9) | 0.323 |
Continuous variables are presented as mean ± SEM
Comparison of postoperative outcomes
| Variable | DLC group | NDLC group |
|
|---|---|---|---|
| ( | ( | ||
| Postoperative complications, | 0.0016 | ||
| Yes | 8 (23.5) | 4 (4.6) | |
| No | 26 (76.5) | 84 (95.4) | |
| Bile leakage, | 4 (11.8) | 1 (1.1) | 0.0079 |
| Pulmonary complication, | 2 (5.9) | 1 (1.1) | 0.129 |
| Surgical site infection, | 2 (5.9) | 0 (0) | 0.0218 |
| Intraabdominal abscess, | 0 (0) | 1 (1.1) | 0.533 |
| Colitis, | 0 (0) | 1 (1.1) | 0.533 |
| Clavien–Dindo classification | |||
| ≥ II, | 6 (17.7) | 4 (4.6) | 0.018 |
| ≥ IIIa, | 3 (8.8) | 2 (2.3) | 0.102 |
| Postoperative hospital stay, days | 9.26 ± 0.60 | 5.89 ± 0.374 | < 0.0001 |
Continuous variables are presented as mean ± SEM
Results of multivariate analysis
| Variable |
| Odds ratio | 95% confidence interval |
|---|---|---|---|
| Male, | 0.0009 | 5.76 | 1.979–19.51 |
| Interval between symptom onset and operation ≥96 h, n (%) | 0.0009 | 6.32 | 2.126–20.15 |
| Interval between symptom onset and admission ≥72 h, | 0.246 | 2.03 | 0.6124–6.870 |
| Anticoagulant therapy, | 0.258 | 1.96 | 0.6054–6.238 |